AIM OF STUDY: To compare rates of treatment interruption because of side effects and completion rates between subjects treated for latent tuberculosis infection (LTBI) by isoniazid (INH) for 6 months and subjects treated with rifampicin (RIF) for 4 months. METHODS: Retrospective analysis of all patients treated for LTBI by INH (1993-2002) or RIF (2004-2007) based on a database including age, gender, prior liver diseases, alcohol consumption, completion rates, time and cause of interruption and monthly analysis of ASAT and ALAT. RESULTS: 624 subjects were included, 426 treated by INH and 198 by RIF. Gender, origin, history of prior hepatic disease and alcohol excess did not differ between groups. Treatment interruption because of hepatotoxicity was significantly higher in the INH group than in the RIF group (6.1% vs 2.0%; p = 0.03). Completion of treatment was significantly higher in the RIF group compared to the INH group (83% vs 74%; p = 0.02). CONCLUSION: A 4-month RIF treatment was associated with significantly less interruption of treatment because of hepatotoxicity and higher completion rates compared to a 6-month INH regimen. These results support the RIF regimen as an alternative to the presently recommended 9 months of INH in clinical practice.
AIM OF STUDY: To compare rates of treatment interruption because of side effects and completion rates between subjects treated for latent tuberculosis infection (LTBI) by isoniazid (INH) for 6 months and subjects treated with rifampicin (RIF) for 4 months. METHODS: Retrospective analysis of all patients treated for LTBI by INH (1993-2002) or RIF (2004-2007) based on a database including age, gender, prior liver diseases, alcohol consumption, completion rates, time and cause of interruption and monthly analysis of ASAT and ALAT. RESULTS: 624 subjects were included, 426 treated by INH and 198 by RIF. Gender, origin, history of prior hepatic disease and alcohol excess did not differ between groups. Treatment interruption because of hepatotoxicity was significantly higher in the INH group than in the RIF group (6.1% vs 2.0%; p = 0.03). Completion of treatment was significantly higher in the RIF group compared to the INH group (83% vs 74%; p = 0.02). CONCLUSION: A 4-month RIF treatment was associated with significantly less interruption of treatment because of hepatotoxicity and higher completion rates compared to a 6-month INH regimen. These results support the RIF regimen as an alternative to the presently recommended 9 months of INH in clinical practice.
Authors: Adelaide H McClintock; McKenna Eastment; Christy M McKinney; Caroline L Pitney; Masahiro Narita; David R Park; Shireesha Dhanireddy; Alexandra Molnar Journal: BMC Infect Dis Date: 2017-02-14 Impact factor: 3.090
Authors: Roberto Dias de Oliveira; Andrea da Silva Santos; Cassia Barbosa Reis; Alessandra de Cássia Leite; Flávia Patussi Correia Sacchi; Rafaele Carla Pivetta de Araujo; Paulo César Pereira Dos Santos; Valeria Cavalcanti Rolla; Leonardo Martinez; Jason Andrews; Julio Croda Journal: Am J Trop Med Hyg Date: 2020-10 Impact factor: 3.707
Authors: Anke L Stuurman; Marije Vonk Noordegraaf-Schouten; Femke van Kessel; Anouk M Oordt-Speets; Andreas Sandgren; Marieke J van der Werf Journal: BMC Infect Dis Date: 2016-06-08 Impact factor: 3.090
Authors: Andreas Sandgren; Marije Vonk Noordegraaf-Schouten; Femke van Kessel; Anke Stuurman; Anouk Oordt-Speets; Marieke J van der Werf Journal: BMC Infect Dis Date: 2016-05-17 Impact factor: 3.090